获得性血友病A的出血风险及止血治疗反应:GTH-AH 01/2010研究结果
该前瞻性研究基于GTH-AH 01/2010队列,评估获得性血友病A(AHA)患者的出血风险及止血治疗疗效。共记录102例患者的289次出血事件,59%的患者在首日后出现141次新发出血,每周测量FVIII活性与出血率显著相关,仅FVIII活性≥50%可消除出血风险,止血治疗报告有效率达96%。
要点
- AHA患者首诊后至部分缓解前新发出血风险高,每周FVIII活性监测有助于评估个体出血风险。
- 仅当FVIII活性达到≥50%时出血风险才被消除,基线WHO体能状态评分0分与较低出血率相关。
- 止血治疗在96%的出血事件中报告有效。
核心结论
- AHA首诊后至部分缓解前新发出血风险持续较高,每周测量的FVIII活性有助于评估个体出血风险。
研究设计与样本
- 前瞻性GTH-AH 01/2010研究,纳入102例患者,基线及每周测量FVIII活性,由治疗医师评估出血事件。
主要发现
- 共记录289次出血,59%的患者在首日后出现141次新发出血,第1至12周平均每患者周0.13次出血。
- 达到部分缓解前平均每患者周0.27次出血。
- 每周测量的FVIII活性与出血率显著相关,仅FVIII活性≥50%可消除出血风险。
- 基线WHO体能状态评分0分(对比更高评分)与较低出血率相关。
- 止血治疗报告对96%的出血有效。
关键数值与推荐
- FVIII活性≥50%为消除出血风险的阈值。
- 第1至12周平均出血率0.13次/患者周,部分缓解前0.27次/患者周。
- 止血治疗有效率为96%。
临床怎么用
- 对AHA患者应每周监测FVIII活性以评估出血风险。
- 止血治疗对多数出血事件有效,但需关注FVIII活性未达≥50%时的持续出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acquired hemophilia A (AHA) is due to autoantibodies against coagulation factor VIII (FVIII) and most often presents with unexpected bleeding. In contrast to congenital hemophilia, the patient's residual FVIII activity does not seem to correlate with the risk of bleeding as suggested from previous studies. Risk factors for bleeding have not been described. We used data from the prospective GTH-AH 01/2010 study to assess the risk of bleeding and the efficacy of hemostatic therapy. FVIII activity was measured at baseline and weekly thereafter. Bleeding events were assessed by treating physicians. A total of 289 bleeds were recorded in 102 patients. There were 141 new bleeds observed starting after day 1 in 59% of the patients, with a mean rate of 0.13 bleed per patient-week in weeks 1 to 12, or 0.27 bleed per patient-week before achieving partial remission. Weekly measured FVIII activity was significantly associated with the bleeding rate, but only achieving FVIII activity ≥50% abolished the risk of bleeding. A good World Health Organization performance status assessed at baseline (score 0 vs higher) was associated with a lower bleeding rate. Hemostatic treatment was reportedly effective in 96% of bleeds. Thus, the risk of new bleeds after a first diagnosis of AHA remains high until partial remission is achieved, and weekly measured FVIII activity may aid in assessing the individual risk of bleeding. These results will help to define future strategies for prophylaxis of bleeding in AHA.
引用
- Holstein K, Liu X, Smith A, et al. Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study. Blood. 2020. PMID: 32268359. doi:10.1182/blood.2019003639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。